|
Market Closed -
Toronto S.E.
15:59:42 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 15.87 CAD | -0.75% |
|
+1.08% | +24.67% |
| 08-21 | Earnings Flash (RX.V) BioSyent Inc. Reports Q2 Revenue C$19.9M | MT |
| 08-20 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 15, 2025. | CI |
| Market Cap | 179M 129M 111M 105M 95.44M 12.25B 180M 1.24B 482M 6.23B 485M 474M 20.67B | P/E 2026 * |
15.9x | P/E 2027 * | 14.8x |
|---|---|---|---|---|---|
| Enterprise Value | 179M 129M 111M 105M 95.44M 12.25B 180M 1.24B 482M 6.23B 485M 474M 20.67B | EV / Sales 2026 * |
2.45x | EV / Sales 2027 * | 2.16x |
| Free-Float |
64.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : BioSyent Inc.
| 1 day | -0.75% | ||
| 1 week | +1.08% | ||
| Current month | -0.75% | ||
| 1 month | +7.59% | ||
| 3 months | +12.95% | ||
| 6 months | +0.51% | ||
| Current year | +24.67% |
| 1 week | 15.5 |  | 16.25 |
| 1 month | 14.6 | | 16.25 |
| Current year | 12.25 | | 16.25 |
| 1 year | 10.65 | | 16.25 |
| 3 years | 7.66 | | 16.25 |
| 5 years | 6.24 | | 16.25 |
| 10 years | 3.13 | | 16.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/31/26 | Tax | Company | -21,100 | 0.1845% | ||
| 7/27/26 | Tax | Company | 300 | 0.0026% | - | |
| 7/22/26 | Tax | Company | 4,600 | 0.0402% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.75% | +1.08% | +31.54% | +95.93% | 129M | |
| +0.28% | -5.97% | +58.34% | +108.22% | 1,034B | |
| +2.01% | -0.71% | +53.07% | +68.99% | 654B | |
| +1.39% | -2.18% | +23.57% | +75.43% | 459B | |
| +1.04% | -4.72% | +33.93% | +36.19% | 343B | |
| -0.27% | +2.88% | +29.29% | +46.96% | 307B | |
| -0.03% | -2.13% | +0.59% | +12.01% | 251B | |
| +1.92% | -0.93% | +52.28% | +70.67% | 237B | |
| +0.59% | -3.05% | -17.52% | -54.89% | 202B | |
| +2.45% | +0.77% | +32.71% | +95.59% | 186B | |
| Average | +1.03% | -2.48% | +29.78% | +55.51% | 367.17B | |
| Weighted average by Cap. | +1.45% | -3.31% | +38.54% | +66.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 73.2M 52.66M 45.42M 42.73M 38.93M 5B 73.6M 505M 197M 2.54B 198M 193M 8.43B | 83.2M 59.85M 51.63M 48.57M 44.24M 5.68B 83.65M 574M 223M 2.89B 225M 220M 9.58B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-01 | $15.87 | -0.75% | 7,395 |
| 26-08-31 | $15.99 | +1.52% | 21,010 |
| 26-08-28 | $15.75 | -1.25% | 34,658 |
| 26-08-27 | $15.95 | +0.69% | 10,858 |
| 26-08-26 | $15.84 | +0.89% | 11,031 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
15.87CAD
Average target price
18.00CAD
Spread / Average Target
+13.42%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Select your edition
All financial news and data tailored to specific country editions
